When was Watgen Medical founded?

Watgen Medical was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Watgen Medical located?

Watgen Medical is headquartered in Vejle, Denmark.

Who is the current CEO of Watgen Medical?

Jesper Norregaard of Watgen Medical. They are also an angel investors in 1 startup.

Which legal entities is Watgen Medical associated with?

Watgen Medical is associated with Watgen Medical A / S and 1 other.

How many employees does Watgen Medical have?

As of Dec 31, 2020, the latest employee count at Watgen Medical is 1.

Is Watgen Medical a funded company?

Watgen Medical is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Sep 10, 2019.

When was the latest funding round of Watgen Medical?

Watgen Medical's latest funding was a $***** Seed round on Sep 10, 2019, with participation from 0 investor.

Where does Watgen Medical rank among its competitors?

Watgen Medical ranks 12th amongst 34 active competitors, of which 8 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Amferia, which secured $4.11M in Dec, 2025.

Who are the top competitors of Watgen Medical?

Watgen Medical's top competitors include Aethlon Medical, Amferia and Cerus. Among them, Amferia secured the most recent funding round in December, 2025.

Watgen Medical - 2026 Company Profile, Team, Funding, Competitors & Financials

Watgen Medical is a seed company based in Vejle (Denmark), founded in 2018 by Toke Reedtz and Peter Bjerring. It operates as a Developer of medical device for treating atopic dermatitis. Watgen Medical has raised $1.8M in funding. The company has 34 active competitors, including 8 funded and 4 that have exited. Its top competitors include companies like Aethlon Medical, Amferia and Cerus.

Company Details

Watgen Medical manufactures medical devices for treating atopic dermatitis. It sterilizes and hydrogenizes tap water for treating skin diseases. Tempered water is the perfect environment for bacteria growth in standard hot water, leading to different skin diseases. The device provides water that is hydrolyzed and the bacterial growth in hydrolyzed water is very slow.

Website: watgenmedical.com
Social
Email ID: *****@watgenmedical.com
Part Of

Key Metrics

Founded Year

2018

Location

Vejle, Denmark

Stage

Seed

Total Funding

$1.8M in 1 round

Latest Funding Round

Seed, Sep 10, 2019, $*****

Investors

Waturu & 2 more

Ranked

12^th among 34 active competitors

Employee Count

1 as on Dec 31, 2020

Similar Companies

Aethlon Medical & 36 more

View Watgen Medical's full profile

Watgen Medical is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Greentech Investor ApS CIN: 37790133 , Denmark, Active	Jun 09, 2016	-	-
Watgen Medical A / S CIN: 39708531 , Denmark, Active	Jul 02, 2018	-	1 (As on Dec 31, 2020)

Watgen Medical has raised a total funding of $1.8M over 1 round. Watgen Medical has 2 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Watgen Medical:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 10, 2019	8179662	Seed	3313625	2848575	2973053	2396793

Access funding benchmarks and valuations. Sign up today!

View details of Watgen Medical's funding rounds and investors

The founders of Watgen Medical are Toke Reedtz and Peter Bjerring. Jesper Norregaard is the CEO of Watgen Medical.

Here are the details of Watgen Medical's key team members:

Toke Reedtz: Founder of Watgen Medical and founder of 1 other company. They serve on the board of 1 company.
Peter Bjerring: Founder of Watgen Medical.
Jesper Norregaard: CEO of Watgen Medical. They are also an angel investor in 1 startup and serve on the board of 1 company.
Contact Info: 1 phone number

Watgen Medical's Board of Directors

Watgen Medical's board has 3 active members. Toke Reedtz is part of team and Thomas Høgh Marschall and Jonathan Sorger are independent board members.

Here is the list of Watgen Medical's board of directors:

Name	Type	Representing	Status	Duration
Toke Reedtz	Team	-	Current	8y 1m
Thomas Høgh Marschall	Independent board member	-	Current	7y 7m
rzkgixu	Independent board member	-	Current	6y 1m
kezvmux	Independent board member	-	Past	1y 4m

View details of Watgen Medical's Founder profiles and Board Members

Watgen Medical's employee count trend

Watgen Medical has 1 employees as of Dec 20. The total employee count is 50.0% lower than what it was in Dec 19. Here is Watgen Medical's employee count trend over the years:

Uncover Watgen Medical's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Watgen Medical include Aethlon Medical, Amferia and Cerus. Here is the list of Top 10 competitors of Watgen Medical, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Aethlon Medical 1999, San Diego (United States), Public	Immunotherapeutic device company combating cancer and life-threatening viral infections	-	NIH, HHS	55/100
2nd	Amferia 2018, Gothenburg (Sweden), Series B	Developer of an anti-infective technology	$7.56M	Almi Invest, Chalmers Ventures & 5 others	55/100
3rd	Cerus 1991, Concord (United States), Public	Provider of pathogen inactivation technology for blood center or hospital blood bank	-	MidCap Financial, Apollo Investment Corporation ... & 4 others	54/100
4th	Cel-Sci 1983, Vienna (United States), Public	Developer of immunotherapy products for the treatment of cancer and infectious diseases	-	Alpha Capital Partners, Midsummer Capital ... & 7 others	53/100
5th	Ondine Biomedical 1999, Vancouver (Canada), Public	Developer of anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections	$798K	Springboard Enterprises	49/100
6th	ARTCLINE 2007, Germany, Series A	Developer of immune cell-based extracorporeal therapies for intensive care medicine	$4.75M	-	47/100
7th	Z-App Kit 2007, Hafnarfjordur (Iceland), Unfunded	Developer of a amplifier and app for killing pathogenic microorganisms	-	-	45/100
8th	PATH EX 2016, Nashville (United States), Series A	Developing blood-cleansing device to remove pathogens from circulating blood	$5M	IAG Capital Partners, JLABS & 9 others	40/100
9th	Larada Sciences 2006, Salt Lake City (United States), Series A	Leading head lice treatment clinics offering fast, safe, effective solutions	$4.46M	Tech Coast Angels, ventureCapital.org & 1 others	36/100
10th	ToeFX 2016, Hamilton (Canada), Seed	Company discovering and developing treatment of toenail fungus (onychomycosis)	$30K	Accelerator Centre, The Forge	35/100
12th	Watgen Medical 2018, Vejle (Denmark), Seed	Developer of medical device for treating atopic dermatitis	$1.8M	Waturu, Green Impact Ventures & 1 others	31/100